Molecular biology of human cancers: An advanced student's textbook

Molecular Biology of Human Cancers: An Advanced Student's Textbook

Volumn , Issue , 2005, Pages 1-508

  Schulz, Wolfgang Arthur ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900916990     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-3186-1     Document Type: Book

References (342)

1. Allgayer H, Heiss MM, Schildberg FW (eds.) Molecular Staging of Cancer. Springer, 2003.
2. Brenner C, Duggan DJ (eds.) Oncogenomics: Molecular Approaches to Cancer. Wiley, 2004
3. Bronchud MH et al (eds.) Principles of Molecular Oncology. Humana Press, 2003
4. Casson AG, Ford CHJ (2003) Molecular Biology of Cancer. BIOS Scientific.
5. Coleman WB, Tsongalis GJ (2001) Molecular Basis of Human Cancer. Humana Press
6. Cowell JK (2001). Molecular Genetics of Cancer. Academic Press.
7. nd ed. Wiley, 2003
8. Epstein RJ (2002) Human Molecular Biology. An Introduction to the Molecular Basis of Health and Disease. Cambridge University Press
9. th ed. Oxford University Press, 2004
10. Lalloo F (2001) Genetics for Oncologists: The Molecular Genetic Basis of Oncological Disorders. REMEDICA Publishing
11. McKinnell RG, Parchment RE (2005) The Biological Basis of Cancer. Cambridge University Press
12. nd ed. Harcourt Publishers, 2001
13. th ed. Marcel Dekker.
14. nd ed. Springer
15. Strachan T, Read AP (2003) Medical Molecular Genetics. BIOS Scientific
16. Strausberg RL (ed.) Cancer Genomics: Disease Markers. IOS Press 2002
17. Sullivan NF. The Molecular Biology of the Cancer Cell. Cambridge University Press, 2002
18. nd ed. McGraw-Hill, 2002
19. Warshawsky D (2002) Molecular Carcinogenesis, CRC Press www.cancerhandbook.net
20. Mitelman F (ed.) Catalog of chromosomal aberrations in Cancer. Wiley, 1998 (with regular updates)
21. nd ed. McGraw-Hill, 2002
22. Knudson AG (2000) Chasing the cancer demon. Annu. Rev. Genet. 34, 1-19
23. Ponder BAJ (2001) Cancer genetics. Nature 411, 336-341
24. Strausberg RL et al (2002) The cancer genome anatomy project: online resources to reveal the molecular signatures of cancer. Cancer Invest. 20, 1038-1050
25. Balmain A, Gray J, Ponder B (2003) The genetics and genomics of cancer. Nat. Genet. 33 Suppl. 238-244
26. Loeb LA, Loeb KR, Anderson JP (2003) Multiple mutations and cancer. PNAS USA 100, 776-781
27. Futreal PA (2004) A census of human cancer genes. Nat. Rev. Cancer 4, 177-183
28. Zhou BBS, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439
29. Hoeijmakers JHJ (2001) Genome maintenance mechanisms preventing cancer. Nature 411, 366-374
30. Elliott B, Jasin M (2002) Double-strand breaks and translocations in cancer. CMLS 59, 373-385
31. Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prevent. 11, 1513-1530
32. Obe G et al (2002) Chromosomal aberrations: formation, identification and distribution. Mutat. Res. 504, 17-36
33. Cherian MG, Jayasurya A, Bay BH (2003) Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat. Res. 533, 201-209
34. Christmann M (2003) Mechanisms of human DNA repair: an update. Toxicology 193, 3-34
35. Cooke MS, Evans MD, Dizdaroglu M, Lunec J (2003) Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 17, 1195-1214
36. D'Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 3, 23-34
37. Dizdaroglu M (2003) Substrate specificities and excision kinetics of DNA glycosylases involved in baseexcision repair of oxidative DNA damage. Mutat Res. 531, 109-126
38. Gisselson D (2003) Chromosome instability in cancer: how, when, and why? Adv. Cancer Res. 88, 1-29
39. Lucci-Cordisco E et al (2003) Hereditary nonpolyposis colorectal cancer and related conditions. Am. J. Med. Genet. 122A, 325-334
40. Powell SN, Kachnic LA (2003) Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 22, 5784-5791
41. Scharer OD (2003) Chemistry and biology of DNA repair. Angew. Chem. 42, 2946-2974
42. Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3, 155-165
43. Townsend D, Tew K (2003) Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogenomics 3, 157-172
44. Varmus HM, Weinberg RA (1993) Genes and the biology of cancer. Scientific American Publishing
45. Hesketh R (1997) The oncogene and tumor suppressor factbook. Academic Press.
46. th ed. 2 vols. Lippincott Williams & Wilkins 2001
47. Lewis TS, Shapiro PS, Ahn NG (1998) Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49-139
48. Bar-Sagi D, Hall A (2000) Ras and Rho GTPases: a family reunion. Cell 103, 227-238
49. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103, 211-225
50. Wilkinson MG, Millar JBA (2000) Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J. 14, 2147-2157
51. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411, 355-365
52. Kerkhoff E, Rapp UR (2001) The Ras-Raf relationship: an unfinished puzzle. Adv. Enzyme Regul. 41, 261-267
53. Savelyeva L, Schwab M (2001) Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett. 167, 115-123
54. Klein G (2002) Perspectives in studies of human tumor viruses. Front Biosci. 7, d268-274
55. Pelengaris S, Khan M, Evan G (2002) c-MYC: more that just a matter of life and death. Nat. Rev. Cancer 2, 764-776
56. Mikkers H, Berns A (2003) Retroviral insertional mutagenesis: tagging cancer pathways. Adv. Cancer Res. 88, 53-99
57. Nilson JA, Cleveland JL (2003) Myc pathways provoking cell suicide and cancer. Oncogene 22, 9007-9021
58. Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. BBA 1653, 25-40
59. nd ed. Wiley & Sons, 2004
60. Weinberg RA (1996) How cancer arises. Sci. Am. 275, 62-70
61. Kinzler KW, Vogelstein B (1997) Gatekeepers and caretakers. Nature 386, 761-762
62. Ruas M, Peters G (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. BBA 1378, F115-177
63. Knudson AG (2000) Chasing the cancer demon. Annu. Rev. Genet. 34, 1-19
64. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408, 307-310
65. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis. Nature 411, 342-348
66. Irwin MS, Kaelin WG (2001) p53 family update: p73 and p63 develop their own identities. Cell Growth Different. 12, 337-349
67. Classon M, Harlow E (2002) The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2, 910-917
68. Gazdar AF, Butel JS, Carbone M (2002) SV40 and human tumours: myth, association or causality? Nat. Rev. Cancer 2, 957-964
69. Leblanc V, May P (2002) Activation et modifications post-traductionnelles de p53 après dommage de l'ADN. Med. Sci. 18, 577-584
70. Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2, 103-112
71. Zheng L, Lee WH (2002) Retinoblastoma tumor suppressor and genome stability. Adv. Cancer Res. 85, 13-50
72. Fridman JS, Lowe SW (2003) Control of apoptosis by p53. Oncogene 22, 9030-9040
73. Hofseth LJ, Hussain SP, Harris CC (2004) p53: 25 years after its discovery. Trends Pharmacol. Sci. 25, 177-181
74. Iwakuma T, Lozano G (2003) MDM2, an introduction. Mol Cancer Res. 1, 993-1000
75. Lowe SW, Sherr CJ (2003) Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Devel. 13, 77-83
76. Vargas DA, Takahashi S, Ronai Z (2003) Mdm2: a regulator of cell growth and death. Adv. Cancer Res. 89, 1-33
77. Santarosa M, Ashworth A (2004) Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. BBA 1654, 105-122
78. Sherr CJ (2004) Principles of tumor suppression. Cell 116, 235-246
79. rd ed. Wiley-VCH
80. Polakis P (2000) Wnt signaling and cancer. Genes Devel. 14, 1837-1851
81. Taipale J, Beachy PA (2001) The Hedgehog and Wnt signalling pathways in cancer. Nature 411, 349-354
82. Attisano L, Wrana JL (2002) Signal transduction by the TGF β superfamily. Science 296, 1646-1647
83. Cantley LC (2002) The Phosphoinositide 3-Kinase pathway. Science 296, 1655-1657
84. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91-100
85. Martin KH et al (2002) Integrin connections map: to infinity and beyond. Science 296, 1652-1653
86. Sears RC, Nevins JR (2002) Signaling networks that link cell proliferation and cell fate. JBC 277, 11617-11620
87. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase/AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501
88. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425, 577-584
89. Heinrich PC et al (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20
90. Knowles MA, Hornigold N, Pitt E (2003) Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochem. Soc. Transact. 31, 597-602
91. Maillard I, Pear WS (2003) Notch and cancer: best to avoid the ups and downs. Cancer Cell 1, 203-205
92. Nickoloff BJ, Osborne BA, Miele L (2003) Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22, 6598-6608
93. Parsons JT (2003) Focal adhesion kinase: the first ten years. J. Cell Sci. 116, 1409-1416
94. Pouysségur J, Lenormand P (2003) Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Eur. J. Biochem. 270, 3291-3299
95. Radtke F, Raj K (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor. Nat. Rev. Cancer 3, 756-767
96. Siegel PM, Massagué J (2003) Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 3:807-820
97. Van Es, Barker N, Clevers H (2003) You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr. Opin. Genet. Devel. 13, 28-33
98. Greten FR, Karin M (2004) The IKK/NF-kappaB activation pathway - a target for prevention and treatment of cancer. Cancer Lett. 206, 193-199
99. Jin H, Varner J (2004) Integrins: roles in cancer development and as treatment targets. Brit. J. Cancer 90, 561-565
100. Lum L, Beachy PA (2004) The hedgehog response network: sensors, switches and routers. Science 304, 1755-1759
101. Slee EA, O'Connor DJ, Lu X (2004) To die or not to die: how does p53 decide? Oncogene 23, 2809-2818
102. Yu H, Jove R (2004) The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4, 97-105
103. Johnson FB, Sinclair DA, Guarante L (1999) Molecular biology of aging. Cell 96, 291-302
104. Los M et al (2001) Caspases: more than just killers? Trends Immunol. 22, 31-34
105. Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296, 1634-1635
106. Wajant H (2002) The Fas signaling pathway: more than a paradigm. Science 296, 1635-1636
107. Brenner C, Le Bras M, Kroemer G (2003) Insights into the mitochondrial signaling pathway: what lessons for chemotherapy? J. Clin. Immunol. 23, 73-80
108. Cory S, Huang DC, Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22, 8590-8607
109. Feldser DM, Hackett JA, Greider CW (2003) Telomere dysfunction and the initiation of genomic instability. Nat. Rev. Cancer 3, 623-627
110. Franke TF et al (2003) PI3K/Akt and apoptosis: size matters. Oncogene 22, 8983-8998
111. Hahn WC (2003) Role of telomeres and telomerase in the pathogenesis of human cancer. J. Clin. Oncol. 21, 2034-2043
112. Kucharczak J et al (2003) To be, or not to be: NFkB is the answer - role of Rel/NFkB in the regulation of apoptosis. Oncogene 22, 8961-8982
113. Schwerk C, Schulze-Osthoff K (2003) Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem Pharmacol. 66, 1453-1458
114. Ben-Porath I, Weinberg RA (2004) When cells get stressed: an integrative view of cellular senescence. J. Clin. Invest. 113, 8-13
115. Castedo M et al (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825-2837
116. Debatin KM, Krammer PH (2004) Death receptors in chemotherapy and cancer. Oncogene 23, 2950-2966
117. Sharpless NE, De Pinho RA (2004) Telomeres, stem cells, senescence, and cancer. J. Clin. Invest. 113, 160-168
118. rd ed. Academic Press
119. Szyf M (ed.) DNA methylation and cancer therapy. Landes Biosciences, online
120. Ross SA (2000) Retinoids in embryonic development. Physiol Rev. 80, 1021-1054
121. Fereira R (2001) The Rb/chromatin connection and epigenetic control: opinion. Oncogene 20, 3128-3133
122. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413
123. Geiman TM, Robertson KD (2002) Chromatin remodeling, histone modifications, and DNA methylation: how does it all fit together. J. Cell. Biochem. 87, 117-125
124. Jacobs JJL, van Lohuizen M (2002) Polycomb repression: from cellular memory to cellular proliferation and cancer. BBA 1602, 151-161
125. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299
126. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415-428
127. Li E (2002) Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 3, 662-673
128. Mueller MM, Fusenig NE (2002) Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 70, 486-497
129. Reik A, Gregory PD, Urnov FD (2002) Biotechnologies and therapeutics: chromatin as a target. Curr. Opin. Genet. Devel. 12, 233-242
130. Costa RH et al (2003) Transcription factors in liver development, differentiation, and regeneration. Hepatology 38, 1331-1347
131. Esteller M (2003) Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv. Exp. Med. Biol. 532, 39-49
132. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. NEJM 349, 2042-2054
133. Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33 Suppl., 245-254
134. Jaffe LF (2003) Epigenetic theories of cancer initiation. Adv. Cancer Res. 90, 209-230
135. Lessard J, Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255-260
136. McLaughlin F, Finn P, La Thangue NB (2003) The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discov Today 8, 793-802
137. Ohlsson R et al (2003) Epigenetic variability and the evolution of human cancer. Adv. Cancer Res. 88, 145-168
138. Otte AP, Kwaks THJ (2003) Gene repression by Polycomb group protein complexes: a distinct complex for every occasion? Curr. Opin. Genet. Devel. 13, 448-454
139. Passaguè E et al (2003) Normal and leukemic hematopoesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics. PNAS USA 100, Suppl.1, 11842-11849
140. Sims III RJ, Nishioka K, Reinberg D (2003) Histone lysine methylation: a signature for chromatin function. Trends Genet. 19, 629-639
141. Walter J, Paulsen M (2003) Imprinting and disease. Semin. Cell Dev. Biol. 14, 101-110
142. Egger G et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463
143. Nakayama M et al (2004) GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell. Biochem. 91, 540-552
144. Roberts CWM, Orkin SH (2004) The SWI/SNF complex - chromatin and cancer. Nat. Rev. Cancer 4, 133-142
145. Weiss L (2000) Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 19, 193-400
146. Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93, 178-193
147. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411, 375-379
148. Murphy PM (2001) Chemokines and molecular basis of cancer. NEJM 354, 833-835
149. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572
150. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392
151. Hajra KM, Fearon ER (2002) Cadherin and Catenin alterations in human cancer. Genes Chromosomes Cancer 34, 255-268
152. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38-47
153. Almholt K, Johnsen M (2003) Stromal cell involvement in cancer. Rec. Res. Cancer Res. 162, 31-42
154. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410
155. Birchmeier C et al (2003) MET, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915-925
156. Brakebusch C, Fässler R (2003) The integrin-actin connection, an eternal love affair. EMBO J. 22, 2324-2333
157. Dvorak HF (2003) How tumors make bad blood vessels and stroma. Am. J. Pathol. 162, 1747-1757
158. Engbring JA, Kleinman HK (2003) The basement membrane matrix in malignancy. J. Pathol. 200, 465-470
159. Ferrara N, Gerber HP, Le Couter J (2003) The biology of VEGF and its receptors. Nat. Med. 9, 669-676
160. Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 3, 362-374
161. Kauffman EC et al (2003) Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol. 169, 1122-1133
162. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary tumors. Nat. Genet. 33, 49-54
163. Subarsky P, Hill RP (2003) The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20, 237-250
164. Balkwill F (2004) Cancer and the chemokine network. Nat. Rev. Cancer 4, 540-550
165. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 4, 118-132
166. Verheul HMW, Voest EE, Schlingemann RO (2004) Are tumours angiogenesis-dependent? J. Pathol. 202, 5-13
167. Melnick A, Licht JD (1999) Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of APL. Blood 93, 3167-3215
168. Faderl S et al (1999) The biology of CML. NEJM 341, 164-172
169. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356
170. Hecht JL, Aster JC (2000) Molecular biology of Burkitt's lymphoma. J. Clin Oncol. 18, 3707-3721
171. Melnick A (2002) Spotlight on APL: controversies and challenges. Leukemia 16, 1893ff (editorial, see also following articles)
172. Salomoni P, Pandolfi PP (2002) The role of PML in tumor suppression. Cell 108, 165-170
173. Shet AS et al (2002) CML: Mechanisms underlying disease progression. Leukemia 16, 1402-1411
174. Mistry AR et al (2003) The molecular pathogenesis of acute promyelocytic leukemia: implications for the clinical management of the disease. Blood Rev. 17, 71-97
175. Passaguè E et al (2003) Normal and leukemic hematopoesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics. PNAS USA 100, Suppl.1, 11842-11849
176. Pitha-Rowe I et al (2003) Retinoid target genes in acute promyelocytic leukemia. Leukemia 17, 1723-1730
177. Tenen TG (2003) Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 3, 89-101
178. Hennessy BT, Hanrahan EO, Daly PA (2004) Non-Hodgkin lymphoma: an update. Lancet Oncol. 5, 341-353
179. Lee SB, Haber DA (2001) Wilms tumor and the WT1 gene. Exp. Cell Res. 264, 74-99
180. Malik K et al (2001) Wilms' tumor: a paradigm for the new genetics. Oncol. Res. 12, 441-449
181. Feinberg AP, Williams BRG (2003) Wilms' tumor as a model for cancer biology. Methods Mol. Biol. 222, 239-248
182. Menke AL, Schedl A (2003) WT1 and glomerular function. Semin. Cell. Dev. Biol. 14, 233-240
183. Schumacher V et al (2003) Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clin. Cancer Res. 9, 2005-2014
184. Shah MM et al (2004) Branching morphogenesis and kidney disease. Development 131, 1449-1462
185. Weedon D et al (eds.) Pathology and genetics of tumours of the skin. IARC Press, 2004
186. Taipale J, Beachy PA (2001) The Hedgehog and Wnt signalling pathways in cancer. Nature 411, 349-354
187. Fuchs E, Raghavan S (2002) Getting under the skin of epidermal morphogenesis. Nat. Rev. Genet. 3, 199-209
188. Ruiz i Altaba, Sánchez P, Dahmane N (2002) Gli and Hedgehog in cancers: tumours, embryos and stem cells. Nat. Rev. Cancer 2, 342-350
189. Zabarovsky ER, Lerman MI, Minna JD (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21, 6915-6935
190. Alonso L, Fuchs E (2003) Stem cells of the skin epithelium. PNAS USA 100 Suppl 1., 11830-11835
191. Bastian BC (2003) Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 22, 3081-3086
192. Bataille V (2003) Genetic epidemiology of melanoma. Eur. J. Cancer. 39, 1341-1347
193. Chin L (2003) The genetics of malignant melanoma: lessons from mouse and man. Nat. Rev. Cancer 3, 559-570
194. Giglia-Mari G, Sarasin A (2003) TP53 mutations in human skin cancers. Hum. Mutat. 21, 217-228
195. Norgauer J et al (2003) Xeroderma pigmentosum. Eur. J. Dermatol. 13, 4-9
196. Perez-Losada J, Balmain A (2003) Stem-cell hierarchy in skin cancer. Nat. Rev. Cancer 3, 434-443
197. Reifenberger J, Schön MP (2003) Epitheliale Hauttumoren: Molekularbiologie und Pathogenesebasierende Therapie. Hautarzt 54, 1164-1170
198. Olivier M et al (2004) TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ. 157, 247-270
199. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87, 159-170
200. Gupta RA, Du Bois R (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1, 11-21
201. Thiagalingam S et al (2001) Mechanisms underlying losses of heterozygosity in human colorectal cancers. PNAS USA 98, 2698-2702
202. Grady WM, Markowitz SD (2002) Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics Hum. Genet. 3, 101-128
203. Van de Wetering M et al (2002) The β-Catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241-250
204. Reddy BS, Rao CV (2002) Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J. Environ. Pathol. Toxicol. Oncol. 21, 155-164
205. Giles RH, van Es JH, Clevers H (2003) Caught up in a Wnt storm: Wnt signaling in cancer. BBA 1653, 1-24
206. Loeb LA, Loeb KR, Anderson JP (2003) Multiple mutations and cancer. PNAS USA 100, 776-781
207. Lucci-Cordisco E et al (2003) Hereditary nonpolyposis colorectal cancer and related conditions. Am. J. Med. Genet. 122A, 325-334
208. Lustig B, Behrens J (2003) The Wnt signaling pathway and its role in tumor development. J. Cancer Res. Clin. Oncol. 129, 199-221
209. Grady WM (2004) Genomic instability and colon cancer. Cancer Metast. Rev. 23, 11-27
210. Koehne CH, Dubois RN (2004) COX-2 inhibition and colorectal cancer. Semin. Oncol. 31 Suppl. 7, 12-21
211. Nelson WJ, Nusse R (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303, 1483-1487
212. Ebele JN et al (eds.) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, 2004
213. Cordon-Cardo C, Cote RJ, Sauter G (2000) Genetic and molecular markers of urothelial premalignancy and malignancy. Scand. J. Urol. Nephrol. Suppl. 205, 82-93
214. Gonzalgo ML, Schoenberg MP, Rodriguez R (2000) Biological pathways to bladder carcinogenesis. Semin. Urol. Oncol. 18, 256-263
215. Brandau S, Bohle A (2001) Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur. Urol. 39, 491-497
216. Knowles MA (2001) What we could do now: molecular pathology of bladder cancer. Mol Pathol. 54, 215-221
217. Hein DW (2002) Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506, 65-77
218. Liu MC, Gelmann EP (2002) P53 gene mutations: case study of a clinical marker for solid tumors. Semin. Oncol. 29, 246-257
219. Bakkar AA et al (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 63, 8108-8112
220. Grimm MO, Burchardt M, Schulz WA (2003) Perspektiven der molekularen Diagnostik am Beispiel des Harnblasenkarzinoms. Urologe 42, 650-659
221. Quek ML et al (2003) Molecular prognostication in bladder cancer: a current perspective. Eur. J. Cancer 39, 1501-1510
222. Thier R et al (2003) Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int. J. Hyg. Environ. Health 206, 149-171
223. van Rhijn BW et al (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 64, 1911-1914
224. Ebele JN et al (eds.) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, 2004
225. Kovacs G et al (1997) The Heidelberg classification of renal cell tumours. J. Pathol. 183, 131-133
226. Davies JA, Perera AD, Walker CL (1999) Mechanisms of epithelial development and neoplasia in the metanephric kidney. Int. J. Dev. Biol. 43, 473-478
227. Friedrich CA. (2001) Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum. Mol. Genet. 10, 763-767
228. Huebner K, Croce CM (2001) FRA3B and other common fragile sites: the weakest links? Nat. Rev. Cancer 1, 214-221
229. Meloni-Ehrig AM (2002) Renal cancer: cytogenetic and molecular genetic aspects. Am. J. Med. Genet. 115, 164-172
230. Bodmer D et al (2002) Understanding familial and non-familial renal cell cancer. Hum. Mol. Genet. 11, 2489-2498
231. Fromm MF (2002) Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 181-182, 299-303
232. Kaelin WG (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673-682
233. Pfeifer GP et al (2002) Methylation of the RASSF1A gene in human cancers. Biol. Chem. 383, 907-914
234. Ambudkar SV et al (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22, 7468-7485
235. Gitlitz BJ, Figlin RA (2003) Cytokine-based therapy for metastatic renal cell cancer. Urol. Clin. North Am. 30, 589-600
236. Safran M, Kaelin WG (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 111, 779-783
237. Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J. Urol. 170, 2163-2172
238. Mulders P, Bleumer I, Oosterwijk E (2003) Tumor antigens and markers in renal cell carcinoma. Urol. Clin. North Am. 30, 455-465
239. Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9, 677-684
240. Vieweg J, Dannull J (2003) Tumor vaccines: from gene therapy to dendritic cells: the emerging frontier Urol. Clin. North Am. 30, 633-643
241. Zbar B, Klausner R, Linehan WM (2003) Studying cancer families to identify kidney cancer genes Annu. Rev. Med. 54, 217-233
242. th ed. 2 vols. Lippincott Williams & Wilkins 2001
243. Modrow S, Falke D, Truyen U (2003) Molekulare Virologie 2nd ed. Spektrum
244. Feitelson MA et al (2001) Genetic mechanisms of hepatocarcinogenesis. Oncogene 21, 2593-2604
245. Kern MA, Breuhahn K, Schirmacher P (2002) Molecular pathogenesis of human hepatocellular carcinoma. Adv. Cancer Res. 86, 67-112
246. Tannapfel A, Wittekind C (2002) Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch. 440, 345-352
247. Thorgeirsson S, Grisham J (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31, 339-346
248. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22, 5093-5107
249. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362, 1907-1917
250. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4, 505-518
251. Jankowski JA et al (1999) Molecular evolution of the metaplasia- dysplasia-adenocarcinoma sequence in the esophagus. Am. J. Pathol. 154, 965-973
252. El-Omar EM et al. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-402
253. Gonzalez CA, Sala N, Capella G (2002) Genetic susceptibility and gastric cancer risk. Int. J. Cancer 100, 249-260
254. Hajra KM, Fearon ER (2002) Cadherin and Catenin alterations in human cancer. Genes, Chromosomes Cancer 34, 255-268
255. Peek RM, Blaser MJ (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas Nat. Rev. Cancer 2, 28-37
256. Correa P (2003) Bacterial infections as a cause of cancer. J. Natl. Cancer Inst. 95, E3
257. Gonzalez CA, Sala N, Capella G (2002) Genetic susceptibility and gastric cancer risk. Int. J. Cancer 100, 249-260
258. Höfler H, Becker KF (2003) Molecular mechanisms of carcinogenesis in gastric cancer. Rec. Res. Cancer Res. 162, 65-72
259. Yuasa Y (2003) Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat. Rev. Cancer 3, 592-600
260. Blaser MJ, Atherton JC (2004) Helicobacter pylori persistence: biology and disease. J. Clin. Invest. 113, 321-333
261. Ushijima T, Sasako M (2004) Focus on gastric cancer. Cancer Cell 5, 121-125
262. Tavassoli FA, Devilee P (eds.) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, 2003
263. Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406, 747-752
264. Scully R, Livingston DM (2000) In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408, 429-432
265. Katzenellenbogen BS, Katzenellenbogen JA (2002) Defining the "S" in SERMs. Science 295, 2380-2381
266. van de Vijver et al (2002) A gene-expression signature as a predictor of survival in breast cancer. NEJM 347, 1999-2009
267. Venkitaraman AR (2000) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171-182
268. McDonnell DP, Norris JD (2002) Connections and regulation of the human estrogen receptor. Science 296, 1642-1644
269. Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp. Cell Res. 284, 99-110
270. Huang et al (2003) Gene expression predictors of breast cancer outcomes. Lancet 361, 1590-1596
271. Keen JC, Davidson NE (2003) The biology of breast carcinoma. Cancer 97 Suppl. 825-833
272. Ramaswamy S et al (2003) A molecular signature of metastasis in primary tumors. Nat. Genet. 33, 49-54
273. Stern DF (2003) ErbBs in mammary development. Exp. Cell Res. 284, 89-98
274. Wooster R, Weber BL (2003) Breast and ovarian cancer. NEJM 348, 2339-2347
275. Jordan VC (2004) Selective estrogen receptor modulation: concept and consequences in the clinic. Cancer Cell 5, 207-213
276. Venkitaraman AR (2004) Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat. Rev. Cancer 4, 266-276
277. Chung LWK, Isaacs WB, Simons JW (eds) Prostate cancer: biology, genetics and the new therapeutics. Humana Press, 2002
278. Ebele JN et al (eds.) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, 2004
279. Koeneman KS, Yeung F, Chung LWK (1999) Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39, 246-261
280. Djakiew D (2000) Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42, 150-160
281. Dong JT (2001) Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metast. Rev. 20, 173-193
282. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45
283. Isaacs W, de Marzo A, Nelson WG (2002) Focus on prostate cancer. Cancer Cell 2, 113-116
284. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic
285. Simard J, Dumont M, Soucy P, Labrie F (2002) Prostate cancer susceptibility genes. Endocrinology 143, 2029-2040
286. Balk SP, Ko YJ, Bubley GJ (2003) Biology of prostate-specific antigen. J. Clin. Oncol. 21, 383-391
287. Gonzalgo ML, Isaacs WB (2003) Molecular pathways to prostate cancer. J. Urol. 170, 2444-2452
288. Schulz WA, Burchardt M, Cronauer MV (2003) Molecular biology of prostate cancer. Mol. Hum. Reprod. 9, 437-448
289. Visakorpi T (2003) The molecular genetics of prostate cancer. Urology 62, Suppl. 1, 3-10
290. Nakayama M et al (2004) GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell. Biochem. 91, 540-552
291. Proctor RN (1995) Cancer wars. BasicBooks
292. Griffiths K, Denis LJ, Turkes A (2002) Oestrogens, phyto-oestrogens and the pathogenesis of prostatic diseases. Martin Dunitz
293. Eng C, Hampel H, de la Chapelle A (2000) Genetic testing for cancer predisposition. Annu. Rev. Med. 52, 371-400
294. Giovannucci E (2002) Epidemiologic studies of folate and colorectal neoplasia: a review. J. Nutr. 132, Suppl. 2350S-2355S
295. Negm RS, Verma M, Srivastava S (2002) The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 8, 288-293
296. Freemantle SJ, Spinella MJ, Dmitrovsky E (2003) Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22, 7305-7315
297. Kensler TW et al (2003) Translational strategies for cancer prevention in liver. Nat. Rev. Cancer 3, 321-329
298. Pollak MN, Foulkes WD (2003) Challenges to cancer control by screening. Nat. Rev. Cancer 3, 297-303
299. Sabichi AL et al (2003) Frontiers in cancer prevention research. Cancer Res. 63, 5649-5655
300. Lerman C, Shields AE (2004) Genetic testing for cancer susceptibility: the promise and the pitfalls. Nat. Rev. Cancer 4, 235-241
301. Golub TR (2001) Genomic approaches to the pathogenesis of hematologic malignancies. Curr. Opin. Hematol. 81, 252-261
302. Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98, 10869-10874
303. Bok RA, Small EJ (2002) Bloodborne biomolecular markers in prostate cancer: development and progression. Nat. Rev. Cancer 2, 918-926
304. Chung CH, Bernard PS, Perou CM (2002) Molecular portraits and the family tree of cancer. Nat. Genet. 32 Suppl. 533-540
305. van't Veer et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536
306. Watters JW, McLeod HL (2002) Recent advances in the pharmacogenetics of cancer chemotherapy. Curr. Opin. Mol. Therapeut. 4, 565-571
307. Widschwendter M, Jones PA (2002) The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin. Cancer Res. 8, 17-21
308. Etzioni R et al (2003) The case for early detection. Nat. Rev. Cancer 3, 243-252
309. Goldstein DB, Tate SK, Sisodiya SM (2003) Pharmacogenetics goes genomic. Nat. Rev. Genet. 4, 937-947
310. Laird PW (2003) The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253-266
311. Liu ET (2003) Classification of cancers by expression profiling. Curr. Opin. Genet. Devel. 13, 97-103
312. Russo G, Zegar C, Giordano A (2003) Advantages and limitations of microarray technology in human cancer. Oncogene 22. 6497-6507
313. Tribut O et al (2003) Pharmacogenomics. Med. Sci. Monit. 8, RA152-163
314. van der Velde VHJ et al (2003) Detection of minimal residual disease in hematological malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17, 1013-1034
315. Friedman T (ed.) The development of human gene therapy. Cold Spring Harbor Laboratory Press, 1999
316. Templeton NS, Lasic DD (eds.) Gene therapy: therapeutic mechanisms and strategies. Marcel Dekker, 2000
317. Stuhler G, Walden P (eds.) Cancer Immune Therapy: Current and Future Strategies. Wiley VCH, 2002
318. Prendergast GC (ed.) Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development. Wiley, 2004
319. Bange J, Zwick E, Ullrich A (2001) Molecular targets for breast cancer therapy and prevention. Nat. Med. 7, 548-552
320. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384
321. Vogelstein B, Kinzler KW (2001) Achilles' heel of cancer? (i.e.p53 inactivation) Nature 412, 865-866
322. Caponigro F (2002) Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Anticancer Drugs 13, 891-897
323. Darnell JE (2002) Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740-749
324. Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2, 188-200
325. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164
326. Arteaga CL (2003) ErbB-targeted therapeutic approaches in human cancer. Exp. Cell Res. 284, 122-130
327. Blackledge G (2003) Growth factor receptor tyrosine kinase inhibitors: clinical development and potential for prostate cancer therapy. J. Urol. 170, S77-S83
328. Deininger MW, Druker BJ (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55, 401-423
329. Fei P, el-Deiry WS (2003) P53 and radiation responses. Oncogene 22, 5774-5783
330. Felscher DW (2003) Cancer revoked: oncogenes as therapeutic targets. Nat. Rev. Cancer 3, 375-379
331. Grünwald V, Hidalgo M (2003) Developing inhibitors of the Epidermal Growth Factor Receptor for cancer treatment. J. Natl. Cancer Inst. 95, 851-867
332. Millar AW, Lynch KP (2003) Rethinking clinical trials for cytostatic drugs. Nat. Rev. Cancer 3, 540-544
333. Nagrasubramanian R, Innocenti F, Ratain MJ (2003) Pharmacogenetics in cancer treatment. Annu. Rev. Med. 54, 437-452
334. Nevins J et al (2003) Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical features in breast cancer outcomes prediction. Hum. Mol. Genet. 12. Spec. No. 2, R153-157
335. Rothenberg ML, Carbone DP, Johnson DH (2003) Improving the evaluation of new cancer treatments: challenges and opportunities. Nat. Rev. Cancer 3, 303-309
336. Sebti SM (2003) Blocked pathways: FTIs shut down oncogenic signals. Oncologist 8 Suppl. 3, 30-38
337. Vlahovic G, Crawford J (2003) Activation of tyrosine kinases in cancer. Oncologist 8, 531-538.
338. Waxman DJ, Schwartz PS (2003) Harnessing apoptosis for improved anticancer gene therapy. Cancer Res. 63, 8563-8572
339. Eskens FALM (2004) Angiogenesis inhibitors in clinical development; where are we now and where are we going. Brit. J. Cancer 90, 1-7
340. Harris M (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5, 292-302
341. Jordan VC (2004) Selective estrogen receptor modulation: concept and consequences in the clinic. Cancer Cell 5, 207-213
342. Wang S, El-Deiry WS (2004) The p53 pathway: targets for the development of novel cancer therapeutics. Cancer Treat. Res. 119, 175-187